Biomarker testing is a necessary tool in the advancing world of precision cancer treatment. According to a new survey released by CancerCare, a leading national cancer support organization, biomarker testing helped physicians tailor therapy for nearly all the respondent patients (93%) whose cancers were tested over the past 3 years.
Read Article

Patients with “early-onset cancer”—that is, cancers that typically do not occur in younger adults (aged 18-39)—had a significantly higher rate of germline mutations than patients with the “young adult cancers” that are typically seen in this age-group (21% vs 13%, respectively; P = .002), according to results of a new study. The results were presented at the 2020 AACR virtual annual meeting and were highlighted at a meeting press cast.
Read Article

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: